Plain-English translation of NCT06176534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer type of drug called CDK4/6 inhibitors (specifically palbociclib or dalpiciclib) combined with hormone therapy works better than traditional chemotherapy for advanced breast cancer with low hormone receptor levels. The researchers want to find out which treatment approach helps patients live longer and with fewer side effects.
For this specific type of breast cancer—one with low hormone receptors—doctors aren't yet sure whether the newer targeted medication or traditional chemotherapy is the better first choice. This trial aims to answer that question so doctors can offer patients the most effective treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either traditional chemotherapy given over two weeks followed by a maintenance phase, or one of the newer CDK4/6 inhibitor medications combined with hormone therapy. You will visit the clinic regularly for treatment, blood tests, and imaging scans to monitor how well the treatment is working and to track any side effects. The trial is comparing these two approaches to see which one helps patients with this type of breast cancer live longer and feel better.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China